Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones

Abstract

Listen

Translate article

On the basis of adverse events reported to the US Food and Drug Administration, it was observed that atorvastatin-associated adverse event reports were 3.1 times more likely to list rosiglitazone or pioglitazone as a concomitant medication compared with simvastatin-associated adverse event reports.